We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
Friday 27th June 2025 13:00 - 14:00 (BST)
Gene therapy has long been heralded as a game-changer in rare disease treatment, yet the path from scientific breakthrough to real-world impact remains complex. The field has seen remarkable advancements, including ‘non-rare’ diseases, while challenges in access, affordability, regulation, and clinical implementation persist.
This 60-minute masterclass will examine whether gene therapy is meeting expectations or if hurdles such as high costs, limited patient access, and uncertain long-term outcomes are slowing progress.
Our expert panel will discuss how the Life Sciences industry, healthcare systems, and policymakers must adapt to make gene therapies a viable reality.
27th Jun 2025 13:00 – 14:00 (BST)
Speakers
CEO, Gene People
Managing Director, Oxygen Strategy
Director, Advanced Therapy Treatment Centre Network Coordination - Cell & Gene Therapy Catapult
Global Vice President of Market Access AscellaHealth
Former Member of the Board of Advisors, ATMPS | Director at NJ Redfern Ltd
Are you ready to transform your skills and unlock your full potential? Now is the time to elevate your training.
Join Now